Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Revolution Medicines, Inc. clinical trials
The registry lists 22 studies whose lead sponsor is Revolution Medicines, Inc. or one of 1 company grouped under it. 13 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the Revolution Medicines, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Revolution Medicines, Inc..
- Revolution Medicines, Inc.20 studiesSame company
Something wrong?
- EQRx, Inc.2 studies →Acquired — became part of Revolution Medicines, Inc., Nov 9, 2023 · source ↗
Something wrong?
Focus areas
Conditions Revolution Medicines, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 22 of 22.
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)RecruitingNCT07252232Phase 3
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingNCT06162221Phase 1/2
- Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic AdenocarcinomaRecruitingNCT07805954Phase 3
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )RecruitingNCT07621718Phase 3
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic AdenocarcinomaRecruitingNCT07491445Phase 3
- Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingNCT06881784Phase 3
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid TumorsRecruitingNCT06445062Phase 1/2
- Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingNCT06128551Phase 1/2
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingNCT07349537Phase 1
- Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCRecruitingNCT07777822Phase 3
- Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingNCT07397338Phase 1/2
- Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingNCT06040541Phase 1
- Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingNCT05379985Phase 1/2
- Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic AdenocarcinomaApproved for marketingNCT07573215
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Active, not recruitingNCT06625320Phase 3
- Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 1
- A Study of Lerociclib in Participants With Advanced Breast CancerTerminatedNCT05085002Phase 2
Sponsor listed in the registry: EQRx, Inc. · First submitted before EQRx, Inc. became part of Revolution Medicines, Inc.
- Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedNCT05054725Phase 2
- Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid TumorsCompletedNCT04774952Phase 1
- Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/2
- Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsStatus unknownNCT03634982Phase 1
- To Evaluate the Comparative Pharmacokinetics of Orally Administered EQ143 in Different Racial and Ethnic PopulationsCompletedNCT04969965Phase 1
Sponsor listed in the registry: EQRx, Inc. · First submitted before EQRx, Inc. became part of Revolution Medicines, Inc.